A Few Takeaways from Our Interview with Sunshine Heart
Long Ideas - On Tuesday September 3rd, we hosted an interview and Q&A with Sunshine Heart (SSH) CEO David Rosa; a transcript of the call is available at … Continue Reading
Read nowAuthor Archives: Jake King
Orexigen’s Stock Is Beating out the Competition: Here’s the Trade
Long Ideas - Last December, we called Orexigen (OREX) the obesity stock to own in 2013. Thus far, we’ve been spot on. Arena (ARNA) and Vivus (VVUS) have … Continue Reading
Read nowCuris Is Expanding An Early Trial of Its Experimental Treatment for Blood Cancers; That’s Good News for Investors
Long Ideas - Curis (CRIS) early in August added two new cohorts to its ongoing Phase I study of CUDC-907 and increased target enrollment in the study from … Continue Reading
Read nowYou Might Own Oncothyreon For all the Wrong Reasons
Most Popular - A recently announced collaboration with Array BioPharma (ARRY) on a small molecule HER2 inhibitor may be the best thing to happen to Oncothyreon (ONTY) since … Continue Reading
Read nowWeekly Rundown: Don’t Miss these Profits the Next Time Around
Long Ideas - It’s been just under five weeks since the PropThink team laid out the investment thesis for Diadexus (DDXS). We said, “We calculate a probability weighted … Continue Reading
Read nowOwn Tekmira for Exposure to RNAi Without Paying Alnylam’s Hefty Premium
Long Ideas - PropThink Subscribers who followed us into Tekmira (TKMR) at $4.70 in mid-April saw the stock touch a recent high of just over $6.00 early last … Continue Reading
Read nowImmunoCellular Stagnates With Trial Read-Out Still Months Away
Most Popular - ImmunoCellular Therapeutics’ (IMUC) on Wednesday the 7th said that the company expects trial results in the fourth quarter of 2013 or first quarter of 2014 … Continue Reading
Read now